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abstract
PURPOSE To evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with
FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).
PATIENTS AND METHODS FPA144-001 was a phase I, open-label, multicenter trial consisting of the following 3
parts: part 1a involved dose escalation in patients with recurrent solid tumors at doses ranging from 0.3 to
15 mg/kg; part 1b involved dose escalation in patients with advanced-stage GEA; and part 2 involved dose
expansion in patients with advanced-stage GEA that overexpressed FGFR2b at various levels (4 cohorts; high,
medium, low, and no FGFR2b overexpression) and 1 cohort of patients with FGFR2b-overexpressing advanced-
stage bladder cancer.
RESULTS Seventy-nine patients were enrolled; 19 were enrolled in part 1a, 8 in part 1b, and 52 in part 2. No
dose-limiting toxicities were reported, and the recommended dose was identified as 15 mg/kg every 2 weeks
based on safety, tolerability, pharmacokinetic parameters, and clinical activity. The most frequent treatment-
related adverse events (TRAEs) were fatigue (17.7%), nausea (11.4%), and dry eye (10.1%). Grade 3 TRAEs
included nausea (2 patients) and anemia, neutropenia, increased AST, increased alkaline phosphatase,
vomiting, and an infusion reaction (1 patient each). Three (10.7%) of 28 patients assigned to a cohort receiving
a dose of $ 10 mg/kg every 2 weeks for $ 70 days reported reversible grade 2 corneal TRAEs. No TRAEs of
grade $ 4 were reported. Five (17.9%; 95% CI, 6.1% to 36.9%) of 28 patients with high FGFR2b-
overexpressing GEA had a confirmed partial response.
CONCLUSION Overall, bemarituzumab seems to be well tolerated and demonstrated single-agent activity as late-
line therapy in patients with advanced-stage GEA. Bemarituzumab is currently being evaluated in combination
with chemotherapy in a phase III trial as front-line therapy for patients with high FGFR2b-overexpressing
advanced-stage GEA.
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INTRODUCTION
Gastroesophageal adenocarcinoma (GEA) represents
the third most common cause of cancer death world-
wide.1 The majority of patients globally present with
advanced-stage disease, in whom the median overall
survival is approximately 11 months with combination
chemotherapy.2 Later lines of systemic therapy such as
ramucirumab,3,4 immunotherapy,5,6 and trifluridine/
tipiracil7 improve survival by only 1 to 2 months compared
with placebo. New effective therapeutics are needed.
Potential therapeutic targets include the fibroblast growth
factor (FGF)/fibroblast growth factor receptor (FGFR)
pathway, which stimulates angiogenesis, transformation,
and proliferation of tumor cells.8 This pathway is medi-
ated by a family of transmembrane tyrosine kinase re-
ceptors encoded by 4 genes (FGFR1-FGFR4).8 Oral
tyrosine kinase inhibitors have demonstrated efficacy in
bladder cancer and cholangiocarcinomas with genetic
alternations, such as mutations or fusions of FGFR1,
FGFR2, and FGFR3 (although minimal activity with
FGFR amplification), but toxicities such as hyper-
phosphatemia, stomatitis, and retinal toxicities have
been reported in association with these agents.9-11 The
FGFR2 receptor has a splice variant, FGFR2b (also known
as FGFR2IIIb, KGFR, or K-sam),12 that is overexpressed
in 2.5%-31.1% of GEAs depending on the antibody and
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demonstrated to be a result of either amplification or aberrant
transcriptional upregulation of the FGFR2 gene,8,17-20 and in
GEA, both FGFR2b overexpression and FGFR2 gene ampli-
fication have been associated with a worse prognosis.21-23
Amplification of the FGFR2 gene is associated with both the
chromosomal instability and genomically stable subgroups of
The Cancer Genome Atlas.15,17-20,24
Bemarituzumab (FPA144) is a first-in-class humanized
immunoglobulin G1 monoclonal antibody specific to the
splice-variant FGFR2b that inhibits binding of the ligands
FGF7, FGF10, and FGF22.25 Specifically, bemarituzumab
does not inhibit binding of FGF23, the ligand responsible
for phosphate and vitamin D metabolism,26 thereby po-
tentially avoiding the risk of hyperphosphatemia associated
with pan-FGFR tyrosine kinase inhibitors.9-11 Bemar-
ituzumab is also glycoengineered for increased affinity for
the human Fc gamma RIIIA receptor expressed on natural
killer cells, enabling enhanced antibody-dependent cell-
mediated cytotoxicity.25 Bemarituzumab has demonstrated
inhibition of FGFR2b phosphorylation and cell proliferation
in FGFR2b-overexpressing gastric cancer xenograft
models.25 Preclinical in vitro and in vivo studies identified
that a bemarituzumab target trough serum concentration of
$ 60 mg/mL achieves maximum efficacy (data on file; Five
Prime Therapeutics, South San Francisco, CA).
In preclinical toxicity studies, bemarituzumab was toler-
ated in doses up to 100 mg/kg administered weekly for
13 weeks to cynomolgus monkeys. Dose-dependent mi-
croscopic corneal atrophy and mammary gland atrophy
were observed in animals receiving treatment but not in
the animals killed at the end of the 15-week recovery
phase, suggesting the findings were reversible (data on
file; Five Prime Therapeutics). This first-in-human, phase I,
dose-escalation and expansion trial of bemarituzumab
(FPA144-001 trial) was designed to evaluate the safety and
recommended dose (RD) of bemarituzumab in patients
with solid tumors and to evaluate the preliminary efficacy in
patients with FGFR2b-overexpressing advanced-stage GEA
or bladder cancer.
PATIENTS AND METHODS
Phase I Patient Population and Trial Design
FPA144-001 was an open-label, multicenter, nonrandomized
trial (ClinicalTrials.gov identifier: NCT02318329).27,28 Please
see Protocol (online only). Informed consent was obtained for
all patients, and the trial was conducted in compliance with
local and national regulations and in accordance with the
ethical principles based on the Declaration of Helsinki.
The trial was designed with 3 parts, 2 parallel dose es-
calations (parts 1a and 1b) and a part 2 expansion (Fig 1).
PART 1








Objective response rate and
duration of response
Baseline and on-treatment
biopsies to evaluate changes
in the tumor microenvironment
Part 1a: Dose escalation 3 + 3
All solid tumors (n = 19)
Part 1b: Dose escalation
Gastric cancer (n = 8), 3 cohorts
3-10 mg/kg
IHC high
Gastric (n = 22)
IHC moderate
Gastric (n = 4)
IHC low
Gastric (n = 9)
IHC negative
Gastric (n = 10)
IHC positive
Bladder (n = 7)
FIG 1. Study design. IHC, immu-
nohistochemistry; PK, pharmaco-
kinetics; RD, recommended dose.
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Patients in part 1a were required to have any locally advanced
or metastatic solid tumor that had progressed after standard
treatment or that was not appropriate for standard treatment.
For parts 1b and 2, patients were required to have histo-
logically documented recurrent or metastatic GEA or bladder
cancer (part 2 only), measurable disease by RECIST version
1.1, and available tumor tissue for retrospective or prospective
evaluation of FGFR2b expression and FGFR2 amplification.
Part 1a. The primary end point of part 1a was to determine
the incidence of grade 3 or 4 adverse events (AEs) and
clinical laboratory abnormalities defined as dose-limiting
toxicities (DLTs). Part 1a followed a standard 3 + 3 dose-
escalation design with 6 cohorts of patients receiving
bemarituzumab at doses of 0.3, 1, 3, 6, 10, and 15 mg/kg
administered intravenously every 2 weeks. Intrapatient
dose escalation was not permitted. Dose-escalation de-
cisions were agreed upon by the investigators and the study
sponsor and based on an assessment of DLTs, AEs, and
laboratory data during a 28-day DLT window.
Part 1b. The primary end point of part 1b was to evaluate
safety and pharmacokinetics (PK) in patients with GEA
based on literature suggesting therapeutic antibodies may
achieve lower serum concentrations in patients with GEA
compared with other solid tumors.29
Part 2. After identification of the RD from parts 1a and 1b,
part 2 enrolled patients with GEA who were assigned to one
of the following cohorts based on the level of FGFR2b
expression in their tumor sample using a centrally per-
formed validated laboratory-developed prototype immu-
nohistochemistry (IHC) assay (LabCorp, Burlington, NC):
cohort 1, high staining ($ 10% of tumor cells with 3+
membranous staining); cohort 2, moderate staining ($ 10%
of tumor cells with 2+ staining and/or , 10% of tumor
cells with 3+ staining); cohort 3, low staining (1+ staining
and/or, 10% of tumor cells with 2+ staining); and cohort
4, negative staining. Initially, enrollment into the high FGFR2b
group also required demonstration of FGFR2 amplification
(FGFR2-to-CEN10 ratio $ 2.0) by fluorescence in situ hy-
bridization (FISH). After observing a 100% correlation in the
first 12 patients between high overexpression by IHC and
gene amplification by FISH, testing for amplification was
conducted retrospectively. Cohort 5 enrolled patients with
FGFR2b-overexpressing bladder cancer.
Treatment and Assessments
Patients were administered bemarituzumab as a 30-minute
intravenous infusion at a dose based on body weight every
2 weeks until disease progression, unacceptable toxicity,
patient or physician decision, or death. Safety was monitored
throughout the study and for 28 days after the last dose of
treatment by history, physical examination, ECG, blood lab-
oratory testing, and ophthalmologic exams. AEs were graded
according to the National Cancer Institute Common Termi-
nology Criteria for Adverse Events (version 4.03). A DLT was
defined as any of the following events occurring in the first 28
days: absolute neutrophil count (ANC) of , 0.5 3 109/L for
. 5 days; febrile neutropenia (fever . 38.3°C with ANC
, 1.03 109/L); platelets, 253 109/L or, 503 109/L with
bleeding requiring medical intervention; grade 3 thrombo-
cytopenia for . 7 days; grade 4 anemia; any grade $ 2
ophthalmologic AE that did not resolve within 7 days; AST or
ALT . 33 the upper limit of normal (ULN) and concurrent
total bilirubin. 23ULN; or any nonhematologic AE of grade
$ 3 (except controlled nausea, vomiting, and diarrhea).
Comprehensive ophthalmologic assessments (fundoscopy,
slit lamp, ocular coherence tomography, and visual acuity)
were conducted during the trial at screening, after 2 doses,
at the time of any ophthalmologic symptoms, and at end
of treatment. Any adverse ophthalmologic events were
deemed events of special interest and followed until res-
olution. Additional slit lamp evaluations of the cornea were
conducted every 6 weeks for the first 6 months (later
amended to be conducted throughout therapy regardless
of duration). Interim safety reviews were conducted by an
independent data safety monitoring board (DSMB) during
part 2 of this study in accordance with the DSMB Charter.
Multiple serum PK samples were collected during the first
dose, followed by collection before and at the end of infusions,
at subsequent dosing cycles, and approximately 28 days after
the last dose. Tumor assessments were performed according
to RECIST version 1.1 during screening and every 6 weeks
from the first dose of bemarituzumab until week 24 and then
every 12 weeks until study treatment discontinuation or
withdrawal of consent. A complete response (CR) or partial
response (PR) required confirmation within 4 to 6 weeks.
Statistical Methods
Up to 30 patients were planned for each cohort in part 2.
Safety and PK analyses were conducted in all patients who
received $ 1 dose of bemarituzumab. Patients were
evaluable for efficacy if they had measurable disease at
study entry and at least 1 postbaseline disease assessment.
Descriptive summary statistics were provided for patient
characteristics, safety, and PK variables.
Objective response rate (ORR) was calculated as the
proportion of patients with best overall response as CR or
PR per RECIST version 1.1. Disease control rate (DCR) was
calculated as the proportion of patients with a best overall
response of CR, PR, or stable disease. Duration of response
(DOR) was calculated as the number of days from the first
documentation of response to the first documentation of
progressive disease or death, whichever occurred earlier.
RESULTS
Baseline Patient Characteristics
From November 24, 2014, to February 16, 2018, 79 pa-
tients at 17 sites across the United States, South Korea, and
Taiwan were enrolled onto the study. Nineteen patients with
solid tumors were enrolled in part 1a (including 3 patients
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with GEA, 6 with colorectal cancer, 2 with biliary cancer, and
1 each with neuroendocrine, submandibular, lung, perito-
neal, esophageal, breast, bladder, and pancreatic cancer), 8
patients with GEA were enrolled in part 1b, and 52 patients
with GEA (n = 45) or bladder cancer (n = 7) were enrolled in
part 2 (Fig 1). Baseline characteristics are listed in Table 1.
The median number of bemarituzumab infusions across all
patients was 4 (range, 1-97 infusions), and for patients with
GEA, the median number of infusions was 5 (range, 1-34
infusions). As of the data cutoff date of February 20, 2019, 1
patient with bladder cancer remained on treatment. The
majority of patients (72.2%) discontinued the study as
a result of radiographic disease progression.
Safety
No DLTs were observed during the part 1a and 1b dose
escalations, and no maximum-tolerated dose was identi-
fied. Seventy-four (93.7%) of 79 patients reported
treatment-emergent AEs (TEAEs). TEAEs reported in$ 10%
of patients by study part are listed in Table 2. The most
frequently reported TEAEs were generally consistent with an
advanced cancer population and included decreased ap-
petite (30.4%), abdominal pain (29.1%), and fatigue
(26.6%).
Treatment-related AEs (TRAEs) were reported in 40 (50.6%)
of 79 patients. Fatigue (17.7%), nausea (11.4%), and dry
eye (10.1%) were the most common TRAEs. Three patients
reported infusion reactions (grades 1-3, in 1 patient each).
Grade 3 or 4 TEAEs occurred in 40 patients (50.6%), and 6
of those patients (7.6%) had grade 3 or 4 TEAEs that were
considered by the investigator to be treatment related.
Eight grade 3 AEs were reported in the 6 patients (nausea
[2 patients] and anemia, neutropenia, increased AST, in-
creased alkaline phosphatase, vomiting, and an infusion
reaction [1 patient each]).
Serious AEs (SAEs) occurred in 23 patients (29.1%), with 6
events in 5 patients (6.3%) assessed as treatment related.














Unknown (n = 11)
Median age, years (range) 59 (25-86) 56 (29-77) 54 (29-70) 60 (50-61) 63 (50-68) 57 (44-77)
Sex, No. (%)
Male 46 (58.2) 31 (55.4) 11 (39.3) 3 (75) 11 (84.6) 6 (54.5)
Female 33 (41.8) 25 (44.6) 17 (60.7) 1 (25) 2 (15.4) 5 (45.5)
Race, No. (%)
Asian 46 (58.2) 42 (75) 23 (82.1) 3 (75) 8 (61.5) 8 (72.7)
White 31 (39.2) 12 (21.4) 3 (10.7) 1 (25) 5 (38.5) 3 (27.3)
American Indian 1 (1.3) 1 (1.8) 1 (3.6) 0 0 0
African American 1 (1.3) 1 (1.8) 1 (3.6) 0 0 0
ECOG PS, No. (%)
0 24 (30.4) 16 (28) 6 (21.4) 0 6 (42.2) 4 (36.4)
1 55 (69.6) 40 (71.4) 22 (78.6) 4 (100) 7 (53.8) 7 (63.6)
Median No. of prior therapies
(range)
3 (1-8) 3 (1-6) 2.5 (1-6) 1.5 (1-4) 3 (2-5) 4 (2-5)
Prior treatment, No. (%)
Platinum/pyrimidine 55 (98.2) 28 (100) 3 (75) 13 (100) 11 (100)
Taxanes 41 (73.2) 19 (67.9) 1 (25) 12 (92.3) 9 (81.8)
Irinotecan 26 (46.4) 9 (32.1) 2 (50) 9 (69.2) 6 (54.5)







Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GEA, gastroesophageal adenocarcinoma.
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Nausea and vomiting were reported in 1 patient, and an
infusion reaction was reported in 1 patient. Any ocular
event that required intervention or drug discontinuation was
deemed an event of special interest and categorized as an
SAE. Three patients reported such ocular events (ulcerative
keratitis, limbal stem-cell deficiency, and corneal dystrophy
in 1 patient each). These 3 ocular events were all corneal
and grade 2, were reported at doses $ 10 mg/kg, and were
reported $ 70 days after the patient’s first dose of bemar-
ituzumab. The patient with ulcerative keratitis presented with
ocular pain on study day 100 while receiving treatment at
a dose of 15mg/kg. Bemarituzumab was held for 1 dose, and
the patient received a topical ophthalmologic antibiotic and
then resumed bemarituzumab without recurrence of the AE.
The patient with limbal stem-cell deficiency presented with
decreased visual acuity on study day 448 while receiving
treatment at a dose of 10 mg/kg. Ophthalmologic exami-
nation revealed conjunctivalization, bemarituzumab
was permanently discontinued, the patient received an an-
tibiotic ointment, and the AE resolved 60 days after the last
dose of study drug. This AE was the only TRAE on the study
resulting in treatment discontinuation. The patient with cor-
neal dystrophy developed myopia on study day 104 (33 days
after the sixth and final dose of bemarituzumab at 15 mg/kg),
which resolved with corticosteroid eye drops. Of the 28 pa-
tients who received bemarituzumab at doses of $ 10 mg/kg
for$ 70 days, ocular events of special interest were reported
in 3 patients (10.7%). In addition, low-grade (grade 1 or 2)
ocular TEAEswere reported in 23 (29.1%) of 79 patients, with
the most common events being dry eye (17.7%) and in-
creased lacrimation (6.3%). No retinal toxicity was reported.
Four patients died on study; 1 patient died as a result of
septic shock, and 3 died as a result of progressive disease,
with no deaths deemed by the investigator as related to
bemarituzumab. No notable difference in the safety profile
was identified based on tumor type (GEA v non-GEA) or
level of FGFR2b expression.
TABLE 2. Adverse Events Occurring . 10% of Patients in the Overall Patient
Population
Preferred Term
No. of Patients (%)
All Events (N = 79) Grade 3 or 4 Events Grade 5 Events
Decreased appetite 24 (30.4) 1 (1.3) 0
Abdominal pain 23 (29.1) 5 (6.3) 0
Fatigue 21 (26.6) 1 (1.3) 0
Nausea 17 (21.5) 2 (2.5) 0
Anemia 16 (20.3) 7 (8.9) 0
Vomiting 15 (19.0) 1 (1.3) 0
Dry eye 14 (17.7) 0 0
Diarrhea 11 (13.9) 0 0
Edema, peripheral 11 (13.9) 1 (1.3) 0
Pyrexia 11 (13.9) 0 0
Constipation 9 (11.4) 1 (1.3) 0
Weight decreased 9 (11.4) 1 (1.3) 0
Dyspnea 8 (10.1) 1 (1.3) 0
Hypoalbuminemia 8 (10.1) 1 (1.3) 0
Pruritus 8 (10.1) 0 0







P1a 0.3 mg/kg (n = 3)
P1a 1 mg/kg (n = 4)
P1a 3 mg/kg (n = 3)
P1a 6 mg/kg (n = 3)
P1a 10 mg/kg (n = 3)
P1a 15 mg/kg (n = 3)
P1b 3 mg/kg (n = 1)
P1b 6 mg/kg (n = 1)
P1b 10 mg/kg (n = 5)
P2 patients with GEA 15 mg/kg (n = 44)



















FIG 2. Mean (6 standard deviation)
bemarituzumab serum concentration
versus time profiles after first dose
(cycle 1, day 1). GEA, gastroesopha-
geal adenocarcinoma; P1a, part 1a;
P1b, part 1b; P2, part 2.
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PK
Bemarituzumab serum concentration versus time profiles
(group mean 6 standard deviation) from cycle 1, dose 1 for
77 of 79 patients (excluding the 2 patients without full dose)
are displayed in Figure 2. Group mean estimated PK pa-
rameters using noncompartmental analysis from 75 of 79
patients (excluding the 4 patients without enough data or
without full dose) are listed in Table 3 by cohort. Bemar-
ituzumab demonstrated nonlinear clearance from 0.3 mg/kg
to 1 mg/kg and approximately linear clearance from 1 mg/kg
to 15 mg/kg in patients, suggesting target-mediated clear-
ance. Maximum concentration (Cmax) increased the dose
proportionally, whereas exposure (area under the curve
[AUC]) did not increase dose proportionally in the nonlinear
dose range (0.3-1 mg/kg). In the linear dose range (1-15
mg/kg), both Cmax and AUC increased dose proportionally. A
slight accumulation of Cmax and trough concentration (Ctrough)
was observed with repeated every-2-week dosing.
A comparison of the PK parameters in the 3 patients with
corneal toxicity versus those in the 25 patients who were
dosed at$ 10 mg/kg for$ 70 days without corneal toxicity
did not identify a clear association based on Cmax, Ctrough, or
AUC; however, analyses are limited by the number of
patients. The dose of 15mg/kg every 2 weeks was identified
as the RD, based on the observed clinical activity, the
safety, and the ability of this dose to achieve the target
trough of $ 60 mg/mL in most of the patient population. In
patients with high FGFR2b-overexpressing GEA, responses
were observed in the 1 patient dosed at 6 mg/kg, 1 of 4
patients dosed at 10 mg/kg, and 3 of 22 patients dosed at
15 mg/kg. All 5 patients with PRs achieved the predicted
target Ctrough at steady-state of $ 60 mg/mL.
Antitumor Activity
Fifty-two (92.9%) of 56 patients with GEA enrolled across
the study (parts 1a and 1b combined) were efficacy
evaluable per protocol, and all received a dose of at least
6 mg/kg every 2 weeks. Twenty-eight of these patients had
tumors that had high FGFR2b overexpression (all FGFR2
amplified by FISH), 4 patients had tumors with moderate
expression, 12 patients had tumors with low expression,
and 8 patients had tumors with no or unknown expression.
All tumors with moderate, low, or no or unknown FGFR2b
expression were nonamplified by FISH (Table 1). The ORR
was 17.9% (95% CI, 6.1% to 36.9%) in patients with GEA
with high FGFR2b overexpression, with a median DOR of
12.6 weeks (range, 9.1-19.1 weeks; Fig 3). Stable disease
was the best observed response in 13 additional patients,
leading to an overall DCR (PR plus stable disease) of 64.3%
(95% CI, 44.1% to 81.4%) in the subgroup with high
FGFR2b overexpression (Fig 4).
TABLE 3. Bemarituzumab Pharmacokinetic Parameter Estimates Using Noncompartmental Analysis for Patients Enrolled in FPA144-001 After
First Dose
Study Part and Dose (mg/kg) No. of Patients Enrolled
Mean 6 SD
Cmax (mg/mL) Ctrough (mg/mL) AUClast (d*mg/mL)
Part 1a (all solid tumors including GEA)
0.3 3 7.96 6 1.14 0.224a 28.3 6 9.50
1 4 22.2 6 6.12 3.57 6 1.07b 115 6 36.2
3 3 71.5 6 18.2 12.8 6 2.98 355 6 82.5
6 3 136 6 17.5 19.2 6 3.39 672 6 83.5
10 3 288 6 7.30 43.6 6 23.4 1,320 6 340
15 3 393 6 185 56.4 6 31.7 1,710 6 310
Part 1b (GEA)
3 1 52.5 9.22 288
6 1 77.0 21.6 529
10 6c 164 6 43.8 35.3 6 14.6 885 6 191
Part 2
15 (GEA) 45d 276 6 59.3 59.5 6 19.2 1,610 6 329
15 (bladder) 7 297 6 57.0 65.4 6 16.0 1,840 6 324
Abbreviations: AUClast, area under the observed concentration-time curve from the time of dosing to the last quantifiable concentration after
first dose; Cmax, maximum observed serum concentration after first dose; Ctrough, observed serum concentration at the end of the first dose
interval; GEA, gastroesophageal adenocarcinoma; SD, standard deviation.
aOnly 1 patient included as a result of 2 of 3 patients with Ctrough below the lower limit of quantification.
bOnly 3 patients included as a result of no data from cycle 1, day 15 for 1 patient as a result of early termination on study.
cOnly 5 patients included as a result of 1 patient receiving a partial dose for first dose.
dOnly 42 patients included as a result of missing data for 3 patients.
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In the 12 patients with GEA with low FGFR2b over-
expression, there was 1 confirmed response (ORR, 8.3%;
95% CI, 0.2% to 38.5%), with a DOR of 18.1 weeks. The
blood from this patient with tumor response tested negative
for FGFR2 circulating tumor DNA amplification. There were
no responses in the subgroups with moderate (n = 4) and
no or unknown (n = 10) FGFR2b overexpression.
Six patients with bladder cancer selected for FGFR2b
overexpression (high, n = 5; and low, n = 1) were evaluable
for efficacy. No responses were observed. Four patients
experienced a best response of stable disease for a median
of 11.3 weeks (range, 10.1-17.6 weeks). Of note, 1 ad-
ditional patient with FGFR2b-overexpressing bladder
cancer was enrolled in part 1a at a dose of 3 mg/kg every 2
weeks. The patient had a history of surgically resected
bladder cancer with recurrent disease that was diagnosed
by positron emission tomography (PET) scan and, on study,
experienced a complete metabolic response by PET scan,
which was ongoing at the time of data cutoff (49 months).
DISCUSSION
This first-in-human study demonstrated that bemar-
ituzumab, an afucosylated monoclonal antibody directed
against FGFR2b, can be safely administered in patients
with advanced cancer at doses up to 15 mg/kg every 2
weeks. Evidence of monotherapy activity was observed in
heavily pretreated patients with high FGFR2b-overexpressing
GEA. The RD was determined to be 15 mg/kg every
2 weeks based on safety and clinical responses observed
at dose levels that achieved the target trough concen-
tration of bemarituzumab. Consistent with selective tar-
geting of FGFR2b by bemarituzumab, AEs associated with
the pan-FGFR oral tyrosine kinase inhibitors, such as
stomatitis and hyperphosphatemia, were not observed
with bemarituzumab. However, reversible TRAEs of grade
2 symptomatic corneal events, which required intervention
and in one case drug discontinuation, were reported in 3
(10.7%) of 28 patients who were treated with a dose of
$ 10 mg/kg for $ 70 days. An analysis of PK parameters
did not identify a clear association between Cmax, Ctrough, or
AUC for corneal events; however, the small number of
patients limits definitive conclusions.
The mechanism of the corneal toxicity is hypothesized
to be a result of inhibition of FGF10, 1 of the 3 growth
factors inhibited by bemarituzumab, and involved in the
regulation of corneal epithelial wound healing.30,31 No
predisposing clinical factors were identified by medical
history review or baseline ophthalmologic examinations in
patients who developed corneal events compared with
those who did not. In addition, no precursor findings were
identified during the every-6-week ophthalmologic eval-
uations in the patients who developed corneal toxicity
compared with those who did not. These analyses are
limited because of the small number and poor prognosis
of patients enrolled in a phase I trial, which lead to a low
number of patients exposed to prolonged dosing (. 70
days) of bemarituzumab.
Monotherapy efficacy has been disappointing with non-
cytotoxic agents in GEA.3,5,32-35 The ORR observed in this
study in advanced-stage patients with high FGFR2b-
overexpressing GEA was 17.9% (95% CI, 6.1% to
36.9%), and the DCR was 64.3% (95% CI, 44.1% to
81.4%). This ORR compares favorably with that of other
noncytotoxic agents in GEA, such as ramucirumab (ORR,
3.2%)3 and checkpoint inhibitors (ORR, 12%-16%)5,6 in
the late-line GEA setting, warranting further evaluation.
Because of the poor prognosis of GEA with first-line ther-
apy, the majority of patients do not receive third-line and
later therapies.4,36-38 The monotherapy activity of bemar-
ituzumab and its lack of significant overlapping toxicities
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FIG 3. Objective response and
duration of follow-up in FGFR2b-
positive gastric cancer.
2424 © 2020 by American Society of Clinical Oncology Volume 38, Issue 21
Catenacci et al
with standard platinum and fluoropyrimidine chemother-
apeutic agents suggest that combining bemarituzumab
with chemotherapy may potentially benefit more patients in
the front-line setting of FGFR2b-overexpressing GEA. Early
safety data suggest that bemarituzumab combined with
oxaliplatin, fluorouracil, and leucovorin (mFOLFOX6) is
t-
olerable in patients with advanced-stage GI cancers,39 and
a randomized, placebo-controlled, phase III study of
mFOLFOX6 with bemarituzumab in patients with newly
diagnosed advanced-stage GEA, the FIGHT trial (Clinical-
Trials.gov identifier: NCT03694522), initiated enrollment in
September 2018.40
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